← Back to Search

Embolization Before Ablation for Kidney Cancer

N/A

Recruiting

Led By Andrew Gunn, MD

Research Sponsored by University of Alabama at Birmingham

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Aged ≥18 years

Tumor stage T1bN0M0 without vascular invasion, adenopathy, or distant metastatic disease

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 30-90days post procedure

Awards & highlights

Study Summary

This trial is testing a new way to treat kidney cancer that involves freezing the tumor and then cutting off its blood supply. They will be closely monitoring patients for safety.

Who is the study for?

The EMBARC trial is for adults with a specific kidney cancer (T1b renal cell carcinoma) that's between 4.1-7cm large, without spread or vascular invasion. Participants must be able to follow the study plan and use effective birth control if they can have children. People with severe kidney issues, part of a syndrome, certain anatomical abnormalities, poor performance status, contrast allergies not helped by meds, or serious blood clotting problems cannot join.Check my eligibility

What is being tested?

This study tests whether doing trans-arterial embolization (TAE) before freezing the tumor (cryoablation) is safe and works well for treating T1b renal cell carcinoma. It's done at multiple centers where everyone gets both treatments in a planned order to see how they do over time.See study design

What are the potential side effects?

Possible side effects from TAE might include pain at the injection site, fever, nausea or vomiting. Cryoablation could cause bleeding around the kidney, damage to nearby organs or tissues and infection.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 18 years old or older.

Select...

My cancer is early stage, has not spread to lymph nodes or other parts of my body, and does not involve blood vessels.

Select...

My kidney tumor is confirmed by imaging tests.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 30-90days post procedure

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~30-90days post procedure

This trial's timeline: 3 weeks for screening, Varies for treatment, and 30-90days post procedure for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

The number of patients experiencing major adverse events defined as anything grade C or above by Society of Interventional Radiology Guidelines.

Trial Design

1Treatment groups

Experimental Treatment

Group I: RCC ParticipantsExperimental Treatment1 Intervention

Receive Trans-arterial embolization (TAE)

0 / 3Eligibility criteria met

Find a Location

Who is running the clinical trial?

University of Alabama at BirminghamLead Sponsor

1,590 Previous Clinical Trials

2,281,329 Total Patients Enrolled

Varian, a Siemens Healthineers CompanyIndustry Sponsor

30 Previous Clinical Trials

7,248 Total Patients Enrolled

Andrew Gunn, MDPrincipal InvestigatorUniversity of Alabama at Birmingham

Media Library

Trans-arterial embolization (TAE) Clinical Trial Eligibility Overview. Trial Name: NCT05410509 — N/A

Kidney Cancer Research Study Groups: RCC Participants

Kidney Cancer Clinical Trial 2023: Trans-arterial embolization (TAE) Highlights & Side Effects. Trial Name: NCT05410509 — N/A

Trans-arterial embolization (TAE) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05410509 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any available slots for participants in this research?

"Clinicaltrials.gov indicates that this particular trial, which was initially published on December 31st 2022 and last updated June 6th 2022, is not actively recruiting participants. However, there are over two thousand five hundred eighty nine other trials currently enrolling volunteers."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

"Embolization Before Ablation of Renal Cell Carcinoma (EMBARC)"

Andrew J. Gunn 2024. ""Embolization Before Ablation of Renal Cell Carcinoma (EMBARC)"". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05410509.

All > Renal Cell Carcinoma